Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Clinical trial allocation in multinational pharmaceutical companies - a qualitative study on influential factors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Inconsistencies in dosage practice in children with overweight or obesity: A retrospective cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Mechanical and vasomotor properties of piglet isolated middle cerebral artery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Modeling Metastatic Colonization in a Decellularized Organ Scaffold-Based Perfusion Bioreactor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Anti-PD-1 Therapy with Adjuvant Ablative Fractional Laser Improves Anti-Tumor Response in Basal Cell Carcinomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Off-Label 9-Valent Human Papillomavirus Vaccination for Actinic Keratosis: A Case Series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Clinical trial allocation in multinational pharmaceutical companies includes country selection and site selection. With emphasis on site selection, the overall aim of this study was to examine which factors pharmaceutical companies value most when allocating clinical trials. The specific aims were (1) to identify key decision makers during country and site selection, respectively, (2) to evaluate by which parameters subsidiaries are primarily assessed by headquarters with regard to conducting clinical trials, and (3) to evaluate which site-related qualities companies value most when selecting trial sites. Eleven semistructured interviews were conducted among employees engaged in trial allocation at 11 pharmaceutical companies. The interviews were analyzed by deductive content analysis, which included coding of data to a categorization matrix containing categories of site-related qualities. The results suggest that headquarters and regional departments are key decision makers during country selection, whereas subsidiaries decide on site selection. Study participants argued that headquarters primarily value timely patient recruitment and quality of data when assessing subsidiaries. The site-related qualities most commonly emphasized during interviews were study population availability, timely patient recruitment, resources at the site, and site personnel's interest and commitment. Costs of running the trials were described as less important. Site personnel experience in conducting trials was described as valuable but not imperative. In conclusion, multinational pharmaceutical companies consider recruitment-related factors as crucial when allocating clinical trials. Quality of data and site personnel's interest and commitment are also essential, whereas costs seem less important. While valued, site personnel experience in conducting clinical trials is not imperative.

OriginalsprogEngelsk
TidsskriftPharmacology Research & Perspectives
Vol/bind5
Udgave nummer3
Sider (fra-til)e00317
ISSN2052-1707
DOI
StatusUdgivet - jun. 2017

ID: 51775919